Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Correction to: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).

Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, Nichols DE, Brandt SD.

Psychopharmacology (Berl). 2018 Nov 15. doi: 10.1007/s00213-018-5117-z. [Epub ahead of print]

PMID:
30443792
2.

Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).

Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, Nichols DE, Brandt SD.

Psychopharmacology (Berl). 2018 Oct 8. doi: 10.1007/s00213-018-5055-9. [Epub ahead of print] Erratum in: Psychopharmacology (Berl). 2018 Nov 15;:.

PMID:
30298278
3.

Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models.

Volgin AD, Yakovlev OA, Demin KA, Alekseeva PA, Kyzar EJ, Collins C, Nichols DE, Kalueff AV.

ACS Chem Neurosci. 2018 Oct 16. doi: 10.1021/acschemneuro.8b00433. [Epub ahead of print]

PMID:
30252437
4.

Changes in Utilization and Expenditures for Medicare Beneficiaries in Patient-centered Medical Homes: Findings From the Multi-Payer Advanced Primary Care Practice Demonstration.

Nichols DE, Haber SG, Romaire MA, Wensky SG; Multi-Payer Advanced Primary Care Practice Evaluation Team.

Med Care. 2018 Sep;56(9):775-783. doi: 10.1097/MLR.0000000000000966.

PMID:
30052548
5.

Author's reply.

Nichols DE.

J Psychopharmacol. 2018 Jul;32(7):821-822. doi: 10.1177/0269881118767648a. No abstract available.

PMID:
29991342
6.

Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).

Nichols DE.

ACS Chem Neurosci. 2018 Oct 17;9(10):2331-2343. doi: 10.1021/acschemneuro.8b00043. Epub 2018 Mar 1.

PMID:
29461039
7.

Is LSD toxic?

Nichols DE, Grob CS.

Forensic Sci Int. 2018 Mar;284:141-145. doi: 10.1016/j.forsciint.2018.01.006. Epub 2018 Feb 2. Review.

PMID:
29408722
8.

N,N-dimethyltryptamine and the pineal gland: Separating fact from myth.

Nichols DE.

J Psychopharmacol. 2018 Jan;32(1):30-36. doi: 10.1177/0269881117736919. Epub 2017 Nov 2.

PMID:
29095071
9.

Psychedelic Drugs in Biomedicine.

Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV.

Trends Pharmacol Sci. 2017 Nov;38(11):992-1005. doi: 10.1016/j.tips.2017.08.003. Epub 2017 Sep 22. Review.

PMID:
28947075
10.

Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).

Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL.

Drug Test Anal. 2018 Feb;10(2):310-322. doi: 10.1002/dta.2222. Epub 2017 Jul 27.

PMID:
28585392
11.

Experimental evaluation of the generalized vibrational theory of G protein-coupled receptor activation.

Hoehn RD, Nichols DE, McCorvy JD, Neven H, Kais S.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):5595-5600. doi: 10.1073/pnas.1618422114. Epub 2017 May 12.

12.

Chemistry and Structure-Activity Relationships of Psychedelics.

Nichols DE.

Curr Top Behav Neurosci. 2018;36:1-43. doi: 10.1007/7854_2017_475. Review.

PMID:
28401524
13.

Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD).

Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, Nichols DE, Halberstadt AL.

Drug Test Anal. 2017 Oct;9(10):1641-1649. doi: 10.1002/dta.2196. Epub 2017 May 10.

14.

Striatal dopamine D1 receptor suppression impairs reward-associative learning.

Higa KK, Young JW, Ji B, Nichols DE, Geyer MA, Zhou X.

Behav Brain Res. 2017 Apr 14;323:100-110. doi: 10.1016/j.bbr.2017.01.041. Epub 2017 Jan 29.

PMID:
28143767
15.

Crystal Structure of an LSD-Bound Human Serotonin Receptor.

Wacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, Lansu K, Schools ZL, Che T, Nichols DE, Shoichet BK, Dror RO, Roth BL.

Cell. 2017 Jan 26;168(3):377-389.e12. doi: 10.1016/j.cell.2016.12.033.

16.

Psychedelics as Medicines: An Emerging New Paradigm.

Nichols DE, Johnson MW, Nichols CD.

Clin Pharmacol Ther. 2017 Feb;101(2):209-219. doi: 10.1002/cpt.557. Epub 2016 Dec 26. Review.

PMID:
28019026
17.

Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).

Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt AL.

Drug Test Anal. 2017 Jan;9(1):38-50. doi: 10.1002/dta.1985. Epub 2016 Jun 6.

18.

Psychedelics.

Nichols DE.

Pharmacol Rev. 2016 Apr;68(2):264-355. doi: 10.1124/pr.115.011478. Review. Erratum in: Pharmacol Rev. 2016 Apr;68(2):356.

19.

Comparison of electrospray ionization and atmospheric pressure photoionization liquid chromatography mass spectrometry methods for analysis of ergot alkaloids from endophyte-infected sleepygrass (Achnatherum robustum).

Jarmusch AK, Musso AM, Shymanovich T, Jarmusch SA, Weavil MJ, Lovin ME, Ehrmann BM, Saari S, Nichols DE, Faeth SH, Cech NB.

J Pharm Biomed Anal. 2016 Jan 5;117:11-7. doi: 10.1016/j.jpba.2015.08.031. Epub 2015 Aug 22.

PMID:
26340558
20.

Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines.

Brandt SD, Elliott SP, Kavanagh PV, Dempster NM, Meyer MR, Maurer HH, Nichols DE.

Rapid Commun Mass Spectrom. 2015 Apr 15;29(7):573-84. doi: 10.1002/rcm.7134.

PMID:
26212274
21.

N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues.

Nichols DE, Sassano MF, Halberstadt AL, Klein LM, Brandt SD, Elliott SP, Fiedler WJ.

ACS Chem Neurosci. 2015 Jul 15;6(7):1165-75. doi: 10.1021/cn500292d. Epub 2015 Jan 21.

22.

The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.

White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, Nichols DE, Malanga CJ, Roth BL.

J Pharmacol Exp Ther. 2015 Jan;352(1):98-109. doi: 10.1124/jpet.114.216820. Epub 2014 Oct 15.

23.

The Heffter Research Institute: past and hopeful future.

Nichols DE.

J Psychoactive Drugs. 2014 Jan-Mar;46(1):20-6.

PMID:
24830182
24.

Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia.

Martin DA, Marona-Lewicka D, Nichols DE, Nichols CD.

Neuropharmacology. 2014 Aug;83:1-8. doi: 10.1016/j.neuropharm.2014.03.013. Epub 2014 Apr 3.

25.

New victims of current drug laws.

Nutt DJ, King LA, Nichols DE.

Nat Rev Neurosci. 2013 Dec;14(12):877. doi: 10.1038/nrn3530-c2. Epub 2013 Oct 23. No abstract available.

PMID:
24149187
26.

Effects of Schedule I drug laws on neuroscience research and treatment innovation.

Nutt DJ, King LA, Nichols DE.

Nat Rev Neurosci. 2013 Aug;14(8):577-85. doi: 10.1038/nrn3530. Epub 2013 Jun 12. Review.

PMID:
23756634
27.

Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands.

Juncosa JI Jr, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE.

ACS Chem Neurosci. 2013 Jan 16;4(1):96-109. doi: 10.1021/cn3000668. Epub 2012 Jul 17.

28.

trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family.

Pigott A, Frescas S, McCorvy JD, Huang XP, Roth BL, Nichols DE.

Beilstein J Org Chem. 2012;8:1705-9. doi: 10.3762/bjoc.8.194. Epub 2012 Oct 8.

29.

Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand.

Clark AH, McCorvy JD, Conley JM, Williams WK, Bekkam M, Watts VJ, Nichols DE.

Bioorg Med Chem. 2012 Nov 1;20(21):6366-74. doi: 10.1016/j.bmc.2012.08.058. Epub 2012 Sep 8.

30.

Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists.

Chemel BR, Bonner LA, Watts VJ, Nichols DE.

Mol Pharmacol. 2012 May;81(5):729-38. doi: 10.1124/mol.111.077339. Epub 2012 Feb 14.

31.

Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease.

McCorvy JD, Watts VJ, Nichols DE.

Psychopharmacology (Berl). 2012 Jul;222(1):81-7. doi: 10.1007/s00213-011-2625-5. Epub 2012 Jan 6.

PMID:
22222862
32.

Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.

Halberstadt AL, Nichols DE, Geyer MA.

Psychopharmacology (Berl). 2012 Jun;221(4):709-18. doi: 10.1007/s00213-011-2616-6. Epub 2012 Jan 6.

33.

Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.

Cueva JP, Chemel BR, Juncosa JI Jr, Lill MA, Watts VJ, Nichols DE.

Eur J Med Chem. 2012 Feb;48:97-107. doi: 10.1016/j.ejmech.2011.11.039. Epub 2011 Dec 3.

34.
35.

Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

Clark AH, McCorvy JD, Watts VJ, Nichols DE.

Bioorg Med Chem. 2011 Sep 15;19(18):5420-31. doi: 10.1016/j.bmc.2011.07.057. Epub 2011 Aug 3.

36.

A 5-HT(2C) receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference.

McCorvy JD, Harland AA, Maglathlin R, Nichols DE.

Neurosci Lett. 2011 Nov 7;505(1):10-3. doi: 10.1016/j.neulet.2011.07.036. Epub 2011 Jul 30.

37.

Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats.

Marona-Lewicka D, Nichols DE.

Behav Pharmacol. 2011 Sep;22(5-6):508-15. doi: 10.1097/FBP.0b013e328349fc31.

38.

Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.

Cueva JP, Gallardo-Godoy A, Juncosa JI, Vidi PA, Lill MA, Watts VJ, Nichols DE.

J Med Chem. 2011 Aug 11;54(15):5508-21. doi: 10.1021/jm200334c. Epub 2011 Jul 14.

39.

Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues.

Bonner LA, Laban U, Chemel BR, Juncosa JI, Lill MA, Watts VJ, Nichols DE.

ChemMedChem. 2011 Jun 6;6(6):1024-40. doi: 10.1002/cmdc.201100010. Epub 2011 Apr 28.

40.

An animal model of schizophrenia based on chronic LSD administration: old idea, new results.

Marona-Lewicka D, Nichols CD, Nichols DE.

Neuropharmacology. 2011 Sep;61(3):503-12. doi: 10.1016/j.neuropharm.2011.02.006. Epub 2011 Feb 23.

41.

Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists.

Bonner LA, Chemel BR, Watts VJ, Nichols DE.

Bioorg Med Chem. 2010 Sep 15;18(18):6763-70. doi: 10.1016/j.bmc.2010.07.052. Epub 2010 Jul 27.

42.

Structural analysis of the extracellular entrance to the serotonin transporter permeation pathway.

Torres-Altoro MI, Kuntz CP, Nichols DE, Barker EL.

J Biol Chem. 2010 May 14;285(20):15369-79. doi: 10.1074/jbc.M109.088138. Epub 2010 Mar 19.

43.

4-aryl-substituted 2,5-dimethoxyphenethylamines: synthesis and serotonin 5-HT(2A) receptor affinities.

Trachsel D, Nichols DE, Kidd S, Hadorn M, Baumberger F.

Chem Biodivers. 2009 May;6(5):692-704. doi: 10.1002/cbdv.200800235.

PMID:
19479848
44.

WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation.

Marona-Lewicka D, Nichols DE.

Behav Pharmacol. 2009 Feb;20(1):114-8. doi: 10.1097/FBP.0b013e3283242f1a.

PMID:
19179855
45.

Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.

Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ 2nd, McCorvy JD, Chester JA, Nichols DE, Watts VJ.

Eur Neuropsychopharmacol. 2009 Feb;19(2):138-46. doi: 10.1016/j.euroneuro.2008.10.002. Epub 2008 Nov 22.

46.

Helix XI contributes to the entrance of the serotonin transporter permeation pathway.

Torres-Altoro MI, White KJ, Rodríguez GJ, Nichols DE, Barker EL.

Protein Sci. 2008 Oct;17(10):1761-70. doi: 10.1110/ps.036749.108. Epub 2008 Jul 15.

47.

Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI.

Marona-Lewicka D, Chemel BR, Nichols DE.

Psychopharmacology (Berl). 2009 Apr;203(2):265-77. doi: 10.1007/s00213-008-1238-0. Epub 2008 Jul 6.

PMID:
18604600
48.

Serotonin receptors.

Nichols DE, Nichols CD.

Chem Rev. 2008 May;108(5):1614-41. doi: 10.1021/cr078224o. Epub 2008 May 14. Review. No abstract available.

PMID:
18476671
49.

High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.

Nichols DE, Frescas SP, Chemel BR, Rehder KS, Zhong D, Lewin AH.

Bioorg Med Chem. 2008 Jun 1;16(11):6116-23. doi: 10.1016/j.bmc.2008.04.050. Epub 2008 Apr 25.

50.

'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines.

Schultz DM, Prescher JA, Kidd S, Marona-Lewicka D, Nichols DE, Monte A.

Bioorg Med Chem. 2008 Jun 1;16(11):6242-51. doi: 10.1016/j.bmc.2008.04.030. Epub 2008 May 6.

Supplemental Content

Loading ...
Support Center